Characterization of BclA1, a putative C. difficile Exosporium Glycoprotein. by Reedy, James 1990-
   
 
 
 
 
 
 
 
 
CHARACTERIZATION OF BCLA1, A PUTATIVE C. difficile 
EXOSPORIUM GLYCOPROTEIN 
Major: Biology 
May 2012 
Submitted to Honors and Undergraduate Research 
Texas A&M University 
in partial fulfillment of the requirements for the designation as 
 
 
UNDERGRADUATE RESEARCH SCHOLAR 
 
A Senior Scholars Thesis 
by 
JAMES BREGG REEDY 
   
 
 
CHARACTERIZATION OF BCLA1, A PUTATIVE C. difficile 
EXOSPORIUM GLYCOPROTEIN 
Approved by: 
 
Research Advisor: Joseph Sorg  
Associate Director, Honors and Undergraduate Research: Duncan MacKenzie 
Major: Biology 
May 2012 
Submitted to Honors and Undergraduate Research 
Texas A&M University 
in partial fulfillment of the requirements for the designation as 
 
 
UNDERGRADUATE RESEARCH SCHOLAR 
 
A Senior Scholars Thesis  
by 
JAMES BREGG REEDY 
  iii 
ABSTRACT 
 
Characterization of BclA1, a Putative C. difficile 
Exosporium Glycoprotein. (May 2012) 
 
James Bregg Reedy 
Department of Biology 
Texas A&M University 
 
Research Advisor: Dr. Joseph Sorg 
Department of Biology 
 
Clostridium difficile is a spore forming, anaerobic bacterium that can cause diarrhea, 
pseudomembranous colitis, and toxic mega colon in susceptible hosts. C. difficile spores 
are highly resistant to extreme chemical and physical environments, and are likely the 
infectious agent. Spores are formed and matured inside of a mother cell and released into 
the environment when the mother cell lyses. During spore formation, a loosely attached 
outer layer, the exosporium, is added before mother cell lysis. The function of the C. 
difficile exosporium is not known, but has been studied in several Bacillus spp. In 
Bacillus cereus, the exosporium is the primary barrier that interacts with the host 
environment, helps the spore adhere to surfaces, and escape phagocytosis by 
macrophages. In C. difficile 630, bclA1 is an orthologue of B. anthracis bclA and B. 
cereus bclA, and is a possible exosporium glycoprotein. Mutant C. difficile strains 
lacking these proteins may have effects on spore adhesion, germination, and spore 
architecture. Here we attempt to mutate C. difficile bclA1 through TargeTron 
technology. Though no mutations were observed, we did isolate erythromycin-resistance 
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colonies, suggesting a mutation had been generated, possibly at another locus. 
Erythromycin-resistance is likely induced by a RAM erythromycin-resistance gene 
activated upon a TargeTron insertional event.  Further studies will be done to determine 
the location of the TargeTron mutation. In addition, to determine if BclA1 is located in 
the C. difficile exosporium, spores with fluorescently tagged bclA1 were generated and 
will be viewed under fluorescent microscopy.
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CHAPTER I 
INTRODUCTION 
Clostridium difficile is a Gram-positive, spore-forming, anaerobic bacterium (28, 35). 
Diseases caused by C. difficile include diarrhea, pseudomembranous colitis, and toxic 
megacolon (28). Epidemiological studies report that C. difficile causes up to one-third of 
antibiotic-associated diarrheal cases, over 50% of all cases of antibiotic-associated 
colitis, and over 90% of all cases of antibiotic-associated pseudomembranous colitis (1, 
33). Outbreaks of C. difficile infections (CDI) are increasing worldwide and the exact 
reasons are unknown (33, 44).  The increase in CDIs is likely multifactorial, including 
more virulent strains and increased antibiotic exposure (33). To limit the spread of C. 
difficile in humans, more research needs to be done to understand how: C. difficile 
spores are generated, how these spores germinate, and how germinated spores colonize a 
host. 
 
C. difficile infections are often precipitated by antibiotic use (28). In healthy individuals, 
the normal intestinal flora is thought to inhibit C. difficile colonization by competing for 
nutrients and / or growth sites or by producing inhibitory molecules (43). However, 
when a patient receives antibiotic treatment for another medical condition, the intestinal 
flora is disrupted and C. difficile spores can germinate, colonize the host, and cause 
disease (43). C. difficile produces two enterotoxins, TcdA and TcdB (Toxin A and Toxin  
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  2 
B respectively), which are responsible for symptoms of disease (22, 26). These toxins 
elicit symptoms through UDP-glucose-dependent glycosylation of Rho family of small 
GTPases in colonic epithelial cells (38). The actions of these toxins cause a loss of 
barrier function of colonic epithelial cells, and massive fluid secretions that cause the 
symptoms of disease (48). Treatment of C. difficile infections annually cost between 
$750 million and $3.2 billion in the United States alone (7, 13, 23, 30). 
 
The production of C. difficile spores inside a host creates a major problem in the 
treatment of a CDI. Antibiotics are commonly prescribed to treat CDIs to kill the 
vegetative cells and stop the spread of disease. However, antibiotics do not affect spores, 
and when antibiotic treatment stops, the spores can germinate, and reinitiate infection. 
Since multiple antibiotic treatments are sometimes needed to treat CDIs, new treatment 
options are needed that either prevent germination of spores or block sporulation of 
vegetative cells.  
 
C. difficile, an anaerobe, must be in the spore form to survive outside of the anaerobic 
intestine environment (19). Once the spores have been ingested, they germinate inside 
the gut to produce actively growing bacilli that produce the toxins necessary for disease 
(22, 26). Sporulation has been studied extensively in Bacillus subtilis and is used as a 
model organism to study spore formation and spore germination. The first stage of spore 
formation occurs when a chromatin filament aligns along the axis of the cell (17). The 
cell then asymmetrically divides into the larger mother cell and forespore (17). The 
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mother cell engulfs the forespore and allows the forespore to be a free-floating structure 
enclosed by two membranes (17). Next the spore is matured by the addition of a 
peptidoglycan cortex and layers of coat proteins (17). Once the spore has fully matured, 
the mother cell can lyse, releasing the spore into the environment (17). C. difficile spores 
cannot produce toxins without first germinating to a vegetative cell, thus it is generally 
accepted that to cause disease, C. difficile spores must germinate inside the host (19). 
 
C. difficile spores are encased in a protein coat that helps protect the spores from harsh 
environments.  Surrounding the coat is an additional structure termed the exosporium 
(16). The exosporium helps the spore resist extreme physical and chemical stresses (16). 
Even though the spore is metabolically dormant, the exosporium proteins must interact 
with the surrounding environment (16).  
 
Bacillus anthracis and Bacillus cereus are both spore-producing bacteria whose spores 
are surrounded by an exosporium. These exosporiums are comprised of two layers: an 
outer, hair-like nap and an inner, basal layer (12). In these bacteria, the exosporium 
appears to be a film-like membrane that loosely envelopes the spore (12). This 
exosporium is the primary physiological barrier that interacts with the environment and 
is often the first point of contact with the immune system of infected hosts (12, 42). In B. 
anthracis the exosporium is a semi-permeable barrier that protects the spore from 
potentially harmful molecules, such as antibodies and hydrolytic enzymes (10, 11). 
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In B. cereus, the exosporium first appears after the mother cell engulfs the forespore. 
(32). During this stage of sporulation, the exosporium appears in the cytoplasm, next to 
the outer forespore membrane (32). In later stages of spore development, the exosporium 
moves further away from its origin toward the polar end of the cell (32). By the late 
stage of spore formation the exosporium has completely engulfed the forespore (32). 
After the spore has matured, the spore is released from the mother cell with the 
exosporium attached (42). 
 
The components of the C. difficile exosporium have yet to be identified. Based upon 
homology to exosporium proteins found in B. anthracis and B. cereus, C. difficile has 
three orthologues: bclA1, bclA2, and bclA3. In B. cereus and B. anthracis, BclA is the 
major glycoprotein that comprises the outer layer of the exosporium (16). BclA is 
comprised of three domains: (i) the N-terminal domain (NTD); (ii) the intermediate 
collagen-like region (CLR); (iii) and the C-terminal domain (CTD) (37, 45, 47). 
 
In Bacillus spp., BclA is suggested to form trimers in the hair-like nap (45). Interactions 
between the three CTD domains on BclA could facilitate trimerization and strong 
resistance to heat, photolytic activity, and detergents (2, 37). The BclA CLR and CTD 
allow B. cereus to adhere to surfaces, while the NTD anchors BclA into the hair-like nap 
of the exosporium (24, 46). In B. anthracis, ExsFA/BxpB incorporates BclA into the 
exosporium (46). No homologues of these proteins are found in C. difficile. 
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While little is known about the C. difficile spore compared to spores of other sporulating 
bacteria, even less is known about the C. difficile exosporium. In C. difficile, bclA1 is a 
predicted exosporium glycoprotein. This gene will be mutated and once confirmed, C. 
difficile spores will be produced and the spore architecture of both the wild-type and 
mutant spores will be analyzed using electron microscopy. Further, we will analyze the 
effect of C. difficile bclA1 on spore germination. Since electron microscopy cannot 
identify the location of BclA1, the gene will be fluorescently tagged to confirm its 
location in the exosporium. 
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CHAPTER II 
METHODS 
Strains and growth conditions 
Table 1contains the bacterial strains and plasmids used in this study. BHIS (Brain Heart 
Infusion [BHI] supplemented with 10% L-cysteine) medium was used to grow C. 
difficile (40). When needed, C. difficile growth was supplemented with 250 µg/mL D-
cycloserine, 50 µg/mL kanamycin, 10 µg/mL thiamphenicol, or 5 µg/mL erythromycin. 
C. difficile strains were grown at 37°C in an anaerobic chamber (10% hydrogen, 5% 
carbon dioxide, 85% nitrogen). Escherichia coli and Bacillus subtilis strains were grown 
at 37°C in LB or BHIS medium supplemented with 20 µg/mL chloramphenicol, 50 
µg/mL kanamycin, or 100 µg/mL ampicillin (25). 
 
Plasmid and strain generation 
Table 2 lists the oligonucleotides used in this study. C. difficile JIR8094 genomic DNA 
was used as a template for PCR amplification of C. difficile bclA1 (31). Generation of a 
TargeTron (Sigma-Aldrich) construct to introduce a mutation into C. difficile bclA1 was 
accomplished in several steps. The TargeTron system creates a mutation in the C. 
difficile genome by insertion of a mobilizable group II intron into the selected gene. The 
intron sequence was targeted to C. difficile bclA1 through an algorithm that generates 
specific DNA primers for PCR. Spicing by Overhand Extension (SOE) PCR was done 
using templates pBL64 and pBL65 (gift from L. Bouillaut and A. L. Sonenshein, Tufts 
University) and primers EBS Universal, bclA1 (666a) EBS1, bclA1 (666a) EBS2, and 
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TABLE 1. Bacterial strains and plasmids 
 
 
 
Plasmid or Strain Key Features Reference 
   
Strains   
E. coli   
HB101 pRK24 that provides conjugation 
machinery and Amp
R
 
(18) 
   
B. subtilis   
Bs49 Tn916 that induces conjugation (29) 
BRS1 bclA1-bsfbfp This Study 
   
C. difficile   
630 Clinical isolate (39) 
JIR8094 Erm
S
-CD630 derivative (31) 
BRC1 bclA1-bsfbfp This Study 
BRC2 Erm
R
 with possible TargeTron 
mutation 
This Study 
Plasmids   
pCR2.1-TOPO Amp
R
, Kan
R
 Invitrogen 
 
pJS107 TargeTron construct derived from 
pBL100, contains Tn916 oriT 
(J. A. Sorg, Texas 
A&M University, 
unpublished data) 
pBsfbfp Kan
R
, B. subtilis fluorescent protein 
derived from pET28 
(6) 
pBR1 bclA1 (666a) Intron fragment in 
pCR2.1 
This Study 
pBR2 bclA1 (666a) Intron fragment in 
pBL100 
This Study 
pBR3 bclA1 (666a) Intron fragment in 
pJS107 
This Study 
pBR4 bclA1 in pCR2.1 This Study 
pBR5 bclA1-bsfbfp in pCR2.1 This Study 
pBR6 bclA1 in pMTL84151 This Study 
pBR7 bclA1-bsfbfp in pMTL84151 This Study 
pBR8 bclA1 (81) Intron fragment in pCR2.1 This Study 
pBR9 bclA1 (81) Intron fragment in pJS107 This Study 
pBR10 pBR7 with Tn916 homology This Study 
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TABLE 2. Oligonucleotide sequences 
 
 
bclA1 (666a) IBS to generate a 350 bp retargeting intron fragment (Table 1, Table 2). 
The intron fragment was cloned into pCR2.1-TOPO (Invitrogen) to create pBR1. pBR1 
was digested with BsrGI/HindIII and the retargeted intron fragment was cloned into the 
E. coli – C. difficile shuttle vector, pJS107, yielding pBR3. A separate retargeting intron 
fragment was created using primers EBS Universal, bclA1 (81) EBS1, bclA1 (81) EBS2, 
bclA1 (81) IBS, and templates pBL64 and pBL65 (Table 1, Table 2). Using the same 
Primer Sequence (5’          3’) 
bclA1 (666a) EBS2 TGAACGCAAGTTTCTAATTTCGGTTGGAAATCGAT
AGAGGAAAGTGTCT 
bclA1 (666a) EBS2 AAAAAAGCTTATAATTATCCTTATTTCCCGTTGGG
GTGCGCCCAGATAGGGTG 
bclA1 (666a) EBS1 CAGATTGTACAAATGTGGTGATAACAGATAAGTC
GTTGGGCCTAACTTACCTTTCTTTGT 
EBSU  CGAAATTAGAAACTTGCGTTCAGTAAC 
5’ bclA1 ATGAGAAATATTATACTTTATTTAAATGATG 
3’ bclA1 TTAAGTCATAACAGTATCAGCTATTC 
3’ bclA1- no stop AGTCATAACAGTATCAGCTATTCTA 
5’ bclA1-FP TAGAATAGCTGATACTGTTATGACTATGGCTAGTT
TTCAATCATTTGGGA 
3’ bsfbfp AATCTAGATTACATAATCGGAAGCACTTTAACG 
3’ bclA1-stp AATCTAGATTAAGTCATAACAGTATCAGCTATTC 
5’ bclA1 prom AAAGATCTGATTGTTTATATATTTATTTTTAAATA
ATAATG 
bclA1 (81) EBS1 CAGATTGTACAAATGTGGTGATAACAGATAAGTC
AATGTTCATAACTTACCTTTCTTTGT 
bclA1 (81) EBS2 CGCAAGTTTCTAATTTCGGTTACTTCTCGATAGAG
GAAAGTGTCT 
bclA1 (81) IBS AAAAGCTTTTGCAACCCACGTCGATCGTGAAGAA
GTAAATGTTGTGCGCCCAGATAGGGTG 
5' Erm(td) GTGTGCTTAAATGGTAAGGAATACTCC 
3' Erm(td) CTTGTTCACATTACTGTGACTGGTT 
  9 
techniques previously stated, the newly created intron fragment was inserted into 
pCR2.1-TOPO and pJS107 to make pBR8 and pBR9, respectively. pBR9 will be used if 
pBR3 is not successful in producing a mutation in C. difficile bclA1; pBR9 uses a 
different intron insertion site than pBR3. pBR3 was transformed into E. coli HB101 
pRK24. E. coli HB101 pRK24 pBR3 was then conjugated with C. difficile strain 
JIR8094 creating C. difficile JIR8094 pBR3. Transconjugants were selected on BHIS 
agar medium containing kanamycin and thiamphenicol (BHIS-TK). Insertion of the 
intron into C. difficile bclA1 was selected by screening transconjugants for erythromycin 
resistance on BHIS agar medium supplemented with erythromycin. Functional 
erythromycin resistance upon intron insertion is provided by the activation of a 
retrotransposable activated marker (RAM). Insertional disruption of C. difficile bclA1 
was determined by PCR of the disrupted gene, the 5’ and 3’ junctions of the intron 
insertion site, and active ErmB RAM (Table 2). The same protocol was used to 
introduce pBR9 into E. coli HB101 pRK24 and to conjugate with C. difficile JIR8094. 
Once a mutation of C. difficile bclA1 had been confirmed, the mutated strain was frozen 
and renamed C. difficile BRC3.  
 
The C. difficile bclA1 gene complement was amplified using primers 5’bclA1 prom and 
3’bclA1-stp, and cloned into pCR2.1-TOPO to create pBR4 (Table 1, Table 2). pBR4 
was digested with XbaI/BglII and the fragment was ligated into pMTL84151 to generate 
pBR6. pMTL84151 is an E. coli – C. difficile shuttle vector that will allow the bclA1 
complement to be transferred into C. difficile (15). 
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The fluorescent gene, bsfbfp, was PCR amplified from pBsfbfp  and fused to C. difficile 
bclA1 via SOE PCR using primers 5’bclA1prom, 3’bclA1-no stop, 5’bclA1-FP, and 
3’bsfbfp (Table 1, Table 2) (6). bclA1-bsfbfp was cloned into pCR2.1-TOPO to create 
pBR5, which was digested with XbaI/BglII. The fragment was ligated into pMTL84151 
to generate pBR7. To allow the fusion gene to be recombinate into the C. difficile 
genome, pBR7 was digested with Fse1 and AscI and ligated with a region of Tn916 
homology, to yield pBR10. pBR10 was transformed into Bacillus subtilis Bs49 (29), to 
generate B. subtilis BRS1, and was conjugated with C. difficile JIR8094. 
Transconjugants were selected on BHIS containing kanamycin and thiamphenicol 
(BHIS-TK). Once a C. difficile strain containing bclA1-Bsfbfp had been confirmed, the 
strain was stored as C. difficile BRC1. 
 
Preparation of C. difficile spores 
Spores from C. difficile strains JIR8094 and BRC1 were prepared as described in (41) 
with the following modifications. Each strain was grown on SMC (90 g BactoPeptone, 5 
g Protease peptone, 1 g NH4SO4, 1.5 g Tris Base) agar medium and allowed to grow for 
4 days at 37°C. Cell growth from each plate was collected and washed five times with 
sterile water. Spores were purified from plate debris by centrifugation at 4,000 rpm, for 
10 minutes, on a 50% sucrose gradient. Spores formed as a pellet during centrifugation, 
while other cells and debris were collected in the gradient interface. To remove the 
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sucrose, the spore pellet was washed five times with water and spores were resuspended 
in water. 
Imaging by phase contrast microscopy 
A sample of purified spores from C. difficile JIR8094 and BRC1 were observed under 
phase contrast microscopy at 400x magnification. C. difficile BRC1 spores were 
visualized and compared to wild-type C. difficile JIR8094 spores. 
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CHAPTER III 
RESULTS 
Introducing a mutation into C. difficile bclA1 
The use of a TargeTron technology has previously been effective in generating 
mutations in C. difficile (21, 27). The TargeTron system uses mobile group II introns to 
introduce site specific mutations. The self-splicing activity of group II introns allows the 
intron to splice out of a mRNA transcript. Mobility of the group II intron (ltrB) is aided 
by LtrA, an intron-encoded protein (IEP) (14). Binding of the IEP to the spliced intron 
creates the ribonucleoprotein (RNP) complex (14, 20). The RNP scans DNA for the 
target site, and is recognized by intron-binding sites 1 and 2 (IBS1 and IBS2), and the 
complementary exon-binding sites 1 & 2 (EBS1 and EBS2) (20). Through reverse 
splicing, the intron RNA is inserted into one strand of the targeted DNA site by the RNP, 
while the IEP cleaves the complementary strand and uses the 3’ end as a primer to begin 
reverse transcribing the intron (20). Once the transcribed intron is ligated into the DNA, 
a stable disruption is made in the coding sequence of the gene.  
In Bacillus spp., bclA has been shown to produce a major glycoprotein of the 
exosporium (5). In C. difficile there are three orthologues of bclA (bclA1, bclA2, bclA3) 
whose functions remain unknown. Mutation of C. difficile bclA1 may affect spore 
adhesion, germination, and spore architecture based off studies of mutations in bclA of 
Bacillus spp. (4). To inactivate C. difficile 630 bclA1, a mobile group II intron was 
retargeted for insertion at nucleotide 666 of C. difficile bclA1 and should insert in the 
  13 
anti-sense orientation with respect to the C. difficile bclA1 coding sequence. The C. 
difficile bclA1 intron insertion site was chosen using an algorithm which generates DNA 
primers specific to that insertion site (http://dna.med.monash.edu.au/~torsten/intron_site 
_finder/).  These primers alter the IBS and EBS sites of the intron using PCR. Using 
pBL64 and pBL65 as templates, a 350 bp retargeting intron sequence was ligated into 
pBL100 to generate pBR2. The pBL100 backbone contains genes for LtrA, 
chloramphenicol resistance (catP), and a retrotransposition-activated selectable marker 
(RAM) that activates erythromycin resistance upon insertion of the intron into the target 
gene. In addition, a second TargeTron construct was made using the same 666 retargeted 
intron as pBR2, except it was ligated into pJS107, to generate pBR3; the pJS107 
backbone is identical to pBL100 except that it contains origin of transfer (oriT) from the 
Tn916 transposon. The Tn916 oriT allows for mobilization of the plasmid from B. 
subtilis to C. difficile through conjugation using Tn916. pBR3 was conjugated into C. 
difficile JIR8094 using B. subtilis as donor, and transconjugants were selected for 
thiamphenicol resistance (Tm
R
); catP provides both thiamphenicol and chloramphenicol 
resistance. Thiamphenicol-resistant strains were grown on BHIS-Erm to select for 
colonies with the activated ErmB RAM marker, suggesting possible C. difficile bclA1 
mutations. Erythromycin resistant colonies were isolated and DNA was extracted. Full-
length C. difficile bclA1 was amplified to screen for the presence of a mutation. If C. 
difficile bclA1 was disrupted, we would observe a 1.8 kb insertion of the intron fragment 
into the 2,082 bp coding sequence of C. difficile bclA1, yielding a 3.8 kb product. Many 
of the PCR products of the erythromycin resistant strains had 3.8 kb fragments when 
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bclA1 was amplified (Fig. 1). To ensure that the retargeted intron has been inserted into 
C. difficile bclA1, the 5’ and 3’ junctions of the 1.8 kb intron in C. difficile bclA1 were 
amplified. The 5’ junction of the mutant gene would produce a 2.5 kb fragment and the 
3’ junction would produce a 1.3 kb fragment. However, no PCR fragments for either the 
5’ or 3’ junction were amplified (Fig. 2). These results suggested that no mutation of C. 
difficile bclA1 was made by pBR3. The production of the 3.8 kb fragment from full 
length C. difficile bclA1 was likely a false positive. An incorrect result for the positive 
control also suggests that this was a failed PCR. Another possibility is the presence of 
erythromycin-resistant colonies were produced by activation of a known, inactive ermB 
gene in C. difficile JIR8094 that provides erythromycin-resistance in the parent C. 
difficile 630, and not from RAM activation (9).  
 
 
 
 
 
 
 
 
 
 
FIG. 1.  Amplification of bclA1 from erythromycin-resistant C. difficile with 
bclA1 666a-targeted TargeTron. Full length bclA1 was amplified and products 
were separated by agarose gel electrophoresis.  Wild type bclA1 – 2 kb, bclA1 + 
TargeTron insertion – 3.8 kb. 
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Since pBR3 did not produce a mutation in C. difficile bclA1, pBR2 was conjugated in to 
C. difficile JIR8094 using E. coli HB101 as a donor. Selection for mutant strains 
followed the same procedure as above, however only the wild-type size of C. difficile 
bclA1 was amplified (Fig. 3). The intron sequence used in pBR2 and pBR3 may have 
targeted the intron into a DNA sequence other than C. difficile bclA1, creating 
erythromycin-resistant colonies. Even though C. difficile bclA1 had not been mutated, 
insertion of the intron could have created a mutation in another gene besides C. difficile 
bclA1.  
 
 
 
 
 
 
 
 
 
 
       C. difficile JIR8094 bclA1   _ 
  JIR8094    1            2            3 
      C. difficile 5’ Junction      _ 
 JIR8094     1           2           3 
        C. difficile 3’ Junction      _ 
  JIR8094     1          2           3 
FIG. 2. Amplification of bclA1 666a-targeted TargeTron insertion junctions 
from potential C. difficile bclA1 mutants. Full length bclA1 was amplified and 
products were separated by agarose gel electrophoresis.  Wild type bclA1 –2 
kb, bclA1 + targetron insertion – 3.8 kb, 5’ TargeTron junction 2.5 kb, 3’ 
TargeTron junction 1.3 kb. 
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Since pBR2 and pBR3 were unsuccessful in producing a mutation in bclA1, another 
TargeTron, pBR9, was made from a new, retargeted intron sequence. The new intron 
sequence was re-targeted for nucleotide 81 of the C. difficile bclA1 coding sequence. 
pBR9 was conjugated into C. difficile JIR8094 using E. coli HB101 as a donor, and 
erythromycin-resistance colonies were isolated as above. Amplification of bclA1 from 
erythromycin-resistant strains indicated that all strains were wild-type for bclA1 (Fig. 4). 
To increase TargeTron expression, C. difficile pBR9 strains on BHIS-TK were streaked 
on BHIS-Erm supplemented with 10 mM iron sulfate; TargeTron expression is driven 
from an iron inducible promoter. Significantly less erythromycin-resistant colonies 
formed on BHIS-Erm Fe medium. Amplification of C. difficile bclA1 from 
erythromycin-resistant, iron-induced strains revealed that all strains were wild-type for 
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FIG. 3. Amplification of bclA1 from erythromycin-resistant C. difficile with 
bclA1 666a-targeted TargeTron of separate conjugation. Full length bclA1 was 
amplified and products were separated by agarose gel electrophoresis.  Wild 
type bclA1 – 2 kb, TargeTron insertion – 3.8 kb. 
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bclA1 (Fig. 5). Thus, no insertion of the intron into C. difficile bclA1 was detected in any 
C. difficile strains conjugated with pBR9.  
 
 
 
 
 
 
 
 
 
Since pBR9 was not able to generate a mutation in C. difficile bclA1, pBR3 was used 
again to try to create a mutation in C. difficile bclA1. pBR3 was conjugated into C. 
difficile JIR8094 using E. coli HB101 as a donor, and erythromycin-resistance colonies 
were isolated as above. Amplification of C. difficile bclA1 from erythromycin-resistant 
strains indicated that all strains were wild-type for bclA1. To determine if erythromycin-
resistance was caused by a spontaneous mutation that activated an ErmB genes already 
present in the C. difficile genome, or from ErmB RAM activation by TargeTron 
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FIG. 4. Amplification of bclA1 from erythromycin-resistant C. difficile with 
bclA1 81-targeted TargeTron. Full length bclA1 was amplified and products 
were separated by agarose gel electrophoresis.  Wild type bclA1 –2 kb, 
TargeTron insertion – 3.8 kb. 
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insertion, erythromycin-resistant strains were screened for an active ErmB RAM. All 
strains were able to amplify an active ErmB RAM, suggesting TargeTron insertion into 
the C. difficile genome creating a mutation somewhere other than C. difficile bclA1 (Fig. 
6). Erythromycin-resistant C. difficile strains were frozen and renamed C. difficile 
BRC2.  
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 5. Amplification of bclA1 from erythromycin-resistant C. difficile with 
iron induced bclA1 81-targeted TargeTron. Full length bclA1 was amplified 
and products were separated by agarose gel electrophoresis.  Wild type bclA1 –
2 kb, targetron insertion – 3.8 kb. 
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Production of C. difficile spores with bclA1-bsfbfp 
Traditionally, using fluorescent reporters to analyze the cellular location of target 
proteins in anaerobic bacteria has been met with frustration.  Most flouorophores require 
molecular oxygen to fold the fluorphore properly.  However, recently a novel, flavin-
based fluorescent protein has been described and allows fluorescence even in the 
absence of oxygen (6). To identify the location of BclA1 in the C. difficile spore 
exosporium, bclA1 was fused to a fluorescent gene, bsfbfp (6). The gene fusion, bclA1-
bsfbfp, was integrated into a pBR7 containing catP and Tn916 homology, to generate 
pBR10. The Tn916 homology region allows recombination of pBR10 into Tn916 of the 
B. subtilis genome to create B. subtilis BRS1. B. subtilis BRS1 was conjugated with C. 
difficile JIR8094 to allow the insertion of Tn916 containing bclA1-bsfbfp into the C. 
difficile genome. Transconjugants were selected on thiamphenicol-containing medium. 
                                               C. difficile JIR8094 ErmR                                              _ 
 1            2             3             4            5            6             7            8            9            10                                                                                              
C. difficile JIR8094 ErmR                                                            _ 
 1          2         3          4         5         6         7         8          9       10       11       12        
13       14        15  
Positive 
Control 
pBR3 
 
FIG. 6. Amplification of ErmB RAM marker from erythromycin-resistant C. 
difficile strains with bclA1 666a-targeted TargeTron. ErmB RAM marker was 
amplified and products were separated by agarose gel electrophoresis. Inactive 
ErmB RAM – 1200 bp, active ErmB RAM – 800 bp.  
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DNA was extracted from thiamphenicol-resistant strains, and bsfbfp was amplified from 
the resulting DNA. The presence of the 786 bp product from amplification of bsfbfp 
confirmed the creation of C. difficile BRC1. To generate spores, C. difficile BRC1 was 
allowed to sporulate on SMC media. C. difficile BRC1 spores were purified and imaged 
under phase contrast microscopy (Fig. 7). Both strains appear to have produced many 
spores of similar size, however, C. difficile BRC1 spores appeared to form more large 
clumps than wild-type spores, suggesting different adhesion properties between the two 
strains. Wild-type C. difficile JIR8094 and C. difficile BRC1 spores will be visualized 
using fluorescent microscopy to identify if: (i) the fluorescent gene is capable of 
producing a fluorescent protein in C. difficile; and (ii) if BclA1 is expressed in and 
deposited on the C. difficile exosporium. 
  
FIG. 7. Phase contrast microscopy of C. difficile spores. (a) Phase contrast image 
of JIR8094 spores (b) BRC1 spores. Images represent 400x magnification. 
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CHAPTER IV 
CONCLUSION 
Surrounding the outer surface of the C. difficile spore is the exosporium. No proteins 
have been identified in the C. difficile exosporium, and the role of the C. difficile 
exosporium is not known, but is thought to play a role in spore adhesion (34). Many 
spore-forming Bacillus spp. produce an exosporium during sporulation. In B. cereus, the 
exosporium is the first layer of the spore to interact with the environment and plays a 
role in spore adhesion, evasion from macrophages, and spore germination (3, 8, 36). In 
both B. cereus and B. anthracis, BclA is the major glycoprotein that comprises the outer 
layer of the exosporium, to form a hair-like nap that surrounds the spore (5, 24). B. 
cereus BclA is thought to be used for spore adhesion and for spore hydrophobicity, 
however the adhesion properties of B. cereus BclA are not fully understood (24). In C. 
difficile 630, bclA1, bclA2, and bclA3 are orthologues of B. cereus bclA and B. anthracis 
bclA, a known exosporium glycoprotein.  Characterization of C. difficile BclA1 could 
lead to an understanding of the function of the C. difficile exosporium and how it enables 
spore adhesion on epithelial cells lining the intestine. 
 
Originally, the C. difficile exosporium was thought to play a minor role in spore 
germination, but now is thought to be a major factor in spore adhesion and cell 
colonization in pathogenesis (34). When C. difficile spores are grown in vitro, the 
exosporium is covered with projections termed “bumps” and “knobs” (34). Upon 
germination, the exosporium produces elongated projections that attach to the media, 
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and are later replaced by a thick, anchor-like structure (34). This large appendage 
appears to attach the spore to the medium, and prevents the spore from being removed 
during washing, agitation in water, solvent baths, or point drying (34). C. difficile BclA1 
is not thought to be the elongated projections protruding from the exosporium, based off 
homology to bclA in B. anthracis, but it is possible that C. difficile BclA1 comprises the 
bumps and knobs seen on the outer-layer of the exosporium. These structures could play 
a role in initial spore adhesion until germination, which results in the production of 
separate protein appendages that bind to the host surface. 
 
To determine the function of C. difficile BclA1, we sought to inactivate the C. difficile 
bclA1 coding sequence. The method we used creates a site specific mutation in bclA1 
utilizing TargeTron technology. We were able to retarget a TargeTron construct to C. 
difficile bclA1 and selected for erythromycin-resistant C. difficile colonies, suggesting a 
mutation had been generated. Originally, amplification of C. difficile bclA1 produced a 
3.8 kb fragment, indicating that the 1.8 kb TargeTron had been inserted into the 2 kb C. 
difficile bclA1 coding sequence. However, upon amplification of the TargeTron 
junctions in C. difficile bclA1, no DNA was amplified, indicating no mutation of C. 
difficile bclA1 was generated. Upon further analysis of the full-length C. difficile bclA1 
coding sequence, we observed wild-type 2 kb fragments, instead of the previous, false-
positive, 3.8 kb fragments. Another attempt to disrupt C. difficile bclA1 was made by 
creation of another TargeTron construct, pBR9, but yielded similar results. Similar 
difficulties arose in attempts to mutate C. difficile bclA2 and bclA3 (Nathan Oehring, 
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Kevin Slaughter and Joseph Sorg, Texas A&M University, personal communication). 
The generation of erythromycin-resistant colonies without having a TargeTron insertion 
in C. difficile bclA1 begs the question: how can erythromycin-resistance arise without 
RAM activation of ErmB? One possibility is a spontaneous mutation activated either of 
the 2 inactive ErmB genes already present in the C. difficile genome (9, 39). Another 
possibility is that ErmB RAM is activated by random insertion of the TargeTron 
construct into the C. difficile genome. Since C. difficile bclA1 shares homology to bclA2 
and bclA3, TargeTron insertion may have happened in either of these genes. To test this 
hypothesis, we amplified C. difficile bclA2 and bclA3 of the erythromycin-resistant 
colonies. This amplification produced wild-type fragments, concluding a mutation was 
not introduced into C. difficile bclA1, bclA2, or bclA3.  
 
Erythromycin-resistant strains were screened for an active ErmB RAM caused by 
TargeTron insertion. All strains had an active ErmB RAM, suggesting that 
erythromycin-resistance is caused by RAM activation and not by a spontaneous mutation 
that activates the C. difficile ermB genes. More importantly, this result indicates RAM 
activation caused by an insertion of the TargeTron into the C. difficile genome, 
somewhere other than C. difficile bclA1, bclA2, or bclA3. This data concludes that a 
mutation has been made in C. difficile, but at an unknown location.  
 
To determine if C. difficile BclA1 is located in the C. difficile exosporium, we tagged C. 
difficile bclA1 with the fluorescent gene bsfbfp. Most fluorescent proteins require 
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molecular oxygen to fluoresce, however, C. difficile is an anaerobe and cannot grow in 
the presence of oxygen. Hence, we used the flavin-based protein, Bsfbfp, which has been 
shown to fluoresce in the absence of oxygen (6). C. difficile spores containing the 
fluorescent gene bclA1-bsfbfp were collected, purified, and compared to wild-type C. 
difficile JIR8094 spores; C. difficile JIR8094 is an erythromycin-sensitive derivative of 
C. difficile 630. Previously, collection of C. difficile JIR8094 spores had been very 
difficult because this strain does not sporulate well on BHIS. Thus, we tested a different 
medium, SMC, to promote sporulation of C. difficile JIR8094. A sample was collected 
and phase-contrast microscopy determined that SMC was successful in inducing 
sporulation of C. difficile JIR8094. SMC was then used to generate spores of C. difficile 
BR1, containing fluorescently tagged C. difficile bclA1. When compared to wild-type 
spores, C. difficile BR1 spores appeared to form more groups of clumped spores, 
suggesting that these spores had different adhesion properties from wild-type. An 
alteration in adhesion properties may be facilitated by the presence of an additional C. 
difficile bclA1 coding sequence found in the fluorescently tagged gene. These 
preliminary results indicated that over-expression of C. difficile BclA1 may influence 
adhesion properties of spores. 
 
Understanding the role of C. difficile BclA1 is important since (i) it will determine part 
of the exosporium function and how the spore interacts with the host environment, and 
(ii) will determine how this protein influences spore germination, adhesion, and 
pathogenesis. In B. anthracis, mutation of BclA enables a decreased germination time. 
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(4). If this is also true for mutation of C. difficile bclA1, the role of the C. difficile 
exosporium can be correlated to C. difficile spore germination. Additionally, if C. 
difficile BclA1 does affect spore adhesion to surfaces, chemical treatments can be found 
that will lead to better sanitation that will decrease the amount of CDI relapse, and to 
decrease the adhesion of C. difficile spores in the intestine. 
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